A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib

Ítems similars

• Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
  per: Jorge, Susan E., et al.
  Publicat: (2015)
• De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
  per: Li, Jing-Wen, et al.
  Publicat: (2019)
• MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
  per: Lennerz, Jochen K., et al.
  Publicat: (2011)
• Targeting MET Amplification as a New Oncogenic Driver
  per: Kawakami, Hisato, et al.
  Publicat: (2014)
• Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
  per: Yoshimura, Katsuhiro, et al.
  Publicat: (2017)